BMC Cancer, 2018 Background Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes.
William P. McGuire +6 more
doaj +1 more source
Exosomal Doxorubicin Reduces the Cardiac Toxicity of Doxorubicin
Nanomedicine, 2015 To test the efficacy and toxicity of exosomal doxorubicin (exoDOX) compared with free doxorubicin.The cytotoxic effects of exoDOX were tested in vitro and in nude mice by measuring the tumor volume. The toxic effects were evaluated by measuring the bodyweight and through histopathologic analyses.
TOFFOLI, GIUSEPPE +8 more
openaire +3 more sources
Cardio-Oncology, 2020 Background Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity.
Jieli Li +7 more
doaj +1 more source
Exposure to Doxorubicin Modulates the Cardiac Response to Isoproterenol in Male and Female Mice
Pharmaceuticals, 2023 Sex is a salient risk factor in the development of doxorubicin-induced cardiotoxicity. Sex differences in the heart’s ability to respond to hypertrophic stimuli in doxorubicin-exposed animals have not been reported.
Kevin Agostinucci +4 more
doaj +1 more source
Aqueous leafextracts of Chromolaena odorata and Tridax procumbens attenuated doxorubicin-induced pulmonary toxicity in Wistar rats [PDF]
, 2021 This study investigated the potential protective role of aqueous leafextracts of Chromolaena odorata and Tridax procumbens against pulmonary toxicity induced by doxorubicin.
Ikewuchi, C.C. +5 more
core +1 more source
Temozolomid und pegyliertes liposomales Doxorubicin in Kombination mit Strahlentherapie in der Ersttherapie von Patienten mit Glioblastom WHO Grad IV – eine Phase I/II – Studie (RNOP – 09) [PDF]
, 2011 Hintergrund: Die EORTC26981/NCIC-CE.3-Studie hatte 2005 zur Etablierung eines neuen Standard-Therapieregimes für das Glioblastom geführt. Obwohl sich Temozolomid hierbei als wirksames Agens gezeigt hatte, bleibt die Prognose für diese Entität sehr ...
Schmid, Christina
core +1 more source
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. [PDF]
PLoS ONE, 2015 Doxorubicin has been shown to inhibit proliferation of cancer cells through proteolytic activation of CREB3L1 (cAMP response element binding protein 3-like 1), a transcription factor synthesized as a membrane-bound precursor.
Bray Denard +7 more
doaj +1 more source
Doxorubicin Selectively Inhibits Brain versus Atrial Natriuretic Peptide Gene Expression in Cultured Neonatal Rat Myocytes [PDF]
, 1999 Doxorubicin is an antineoplastic agent with significant cardiotoxicity. We examined the effects of this agent on the expression of the natriuretic peptide (NP) genes in cultured neonatal rat atrial myocytes.
Gardner, D. G. +2 more
core +1 more source
BMC Veterinary Research, 2021 Background Both human and veterinary cancer chemotherapy are undergoing a paradigm shift from a “one size fits all” approach to more personalized, patient-oriented treatment strategies.
Kristine Walters +9 more
doaj +1 more source
TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC
Tumor Biology, 2017 The anticancer effect of doxorubicin is closely related to the generation of reactive oxygen species. On the contrary, doxorubicin-induced reactive oxygen species induces heart failure, a critical side effect of doxorubicin.
Yun Sun Lee +5 more
doaj +1 more source